. Identification of the Jak2V617F mutation by direct DNA sequencing and dHPLC analysis in polycythemia vera. RNA was isolated and cDNA was prepared from the chronic myelogenous leukemia (CML) cell line K562, the erythroleukemia cell line HEL, and peripheral blood from patients with polycythemia vera, obtained with informed consent and according to institutional protocol approved by the Department of Clinical Medicine at Mannheim University of Heidelberg, per the Declaration of Helsinki. (A) Chromatograms of peripheral-blood samples from patients with polycythemia vera after direct sequencing of the forward strand of a PCR-amplified V617 proximal region in Jak2 is shown. The arrows indicate the position of the base implicated in the V617F substitution. The bottom panels show the expected mRNA and protein sequence in Jak2 (wild-type) and Jak2 with the V617F substitution. (B-C) A V617 proximal region within Jak2 was amplified by PCR, digested by Surveyor enzyme, and subjected to dHPLC analysis. Test samples (solid line) were compared to a control sample (dashed line). The arrows indicate the expected retention of the fragments in the presence of the V617F mutation. Chromatograms of peripheral-blood samples from patients with polycythemia vera (B) or HEL-cell samples indicated as a relative percentage of cells in a mixture with K562-cell samples (C) are shown. To the editor:
KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia
Little progress has been made in improving the survival of infants with high-risk acute lymphoblastic leukemia (ALL). 1,2 Prospective studies with intent-to-transplant design 3 or retrospective studies controlling for time-to-transplantation 4 have failed to demonstrate that hematopoietic-cell transplantation (HCT) improves outcome. The antileukemic activity of natural killer (NK) cells was thought to be effective only for acute myeloid leukemia. 5 However, in a recent study, childhood ALL cells were also susceptible to NK-cell lysis when the donor NK cells expressed inhibitory killer-cell immunoglobulin-like receptors (KIRs) in the absence of cognate ligand in the recipient (receptor-ligand mismatch). 6, 7 Notably, in vitro assays and in vivo mouse models demonstrated that human leukemic cells with 11q23 rearrangement were also susceptible to NK-cell alloreactivity. 7 A 3-month-old girl with t(4;11)(q21;q23) CD10 Ϫ ALL presented with a leukocyte count of 479 000/mm 3 . After exchange Recipient HLA and donor KIR typing demonstrated the absence of HLA-C Asn80 ligand in the patient for KIR2DL3, which was present in the donor. This leads to a prediction of NK-cell alloreactivity by the KIR receptor-ligand model. 
